OSI-027は一種の選択性的で、有効な二重mTORC1とmTORC2抑制剤で、無細胞試験でIC50値が22 nM と65 nMに分かれて、mTORに作用する選択性はPI3Kα、PI3Kβ、PI3Kγ或いは DNA-PKに作用する選択性より100倍余りが高くなります。臨床1期。

価格 在庫  
USD 151 あり
USD 252 あり
USD 264 あり
USD 718 あり

OSI-027 化学構造
分子量: 406.44





  • Compare mTOR Inhibitors
  • 研究分野
  • Combination Therapy



製品説明 OSI-027は一種の選択性的で、有効な二重mTORC1とmTORC2抑制剤で、無細胞試験でIC50値が22 nM と65 nMに分かれて、mTORに作用する選択性はPI3Kα、PI3Kβ、PI3Kγ或いは DNA-PKに作用する選択性より100倍余りが高くなります。臨床1期。




22 nM [1]

65 nM [1]

In vitro試験 OSI-027 shows the selective and ATP competitive inhibition activities against mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. In addition, OSI-027 inhibits mTOR signaling of phospho-4E-BP1 with an IC50 of 1 μM in cell-based assays. [1] OSI-027 exhibits anti-proliferative activities against several acute leukemia cell lines of myeloid/megakaryocytic origin in a dose-dependent manner, including U937, KG-1, KBM-3B, ML-1, HL-60, and MEG-01 cells. [2] A recent study shows that inhibition of mTORC1/2 by OSI-027 effectively suppresses phosphorylation of Akt (S473) and cell proliferation in breast cancer cells. [3]
In vivo試験 In GEO colorectal xenograft, OSI-027 (65 mg/kg) inhibits both mTORC1 and mTORC2 effectors, including 4E-BP1, Akt, and S6 phosphorylation. Furthermore, mTORC1 and mTORC2 inhibition together by OSI-027 potently inhibits tumor growth more than mTORC1 inhibition by rapamycin. [1]
臨床試験 OSI-027 is currently in Phase I clinical trials in patients with Advanced Solid Tumors or Lymphoma.

プロトコル (参考用のみ)



Biochemical assays mTORC1 and mTORC2 inhibition is assayed using native enzyme complex immunoprecipitated from HeLa lysates at 1 mM ATP. To prepare whole cell lysates from HeLa cells, 25 g cell pellet is lysed in 60 mL of ice-cold buffer A [40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM glycerophosphate, 50 mM NaF, 0.5 mM orthovanadate, and EDTA-free protease inhibitors containing 0.3% CHAPS] for 30 minutes on a magnetic stirrer in a cold room. After clearing of the lysates by centrifugation at 13,000 g for 10 minutes, Protein G-coated 384-well plates are incubated with 0.25 μg of mTOR antibody in 15 μL of buffer A for 1 hour at 4 °C. To each well, 40 μg of HeLa cell lysate in 15 μL of buffer A is added and incubated overnight at 4 °C to immunoprecipitate mTOR complexes. Plates are washed 3 times with buffer A and twice with immunoprecipitation wash buffer [Buffer B: 50 mM HEPES (pH 7.5) and 150 mM NaCl]. OSI-027 is added at 10 μM concentration to each well and DMSO is added to the control wells. The reaction is started by adding 150 ng of His-tagged 4E-BP1 as a substrate in the presence or absence of 100 μM ATP to each well in 25 μL of freshly prepared kinase buffer [Buffer C: 20 mM HEPES (pH 7.5), 10 mM MgCl2, 4 mM MnCl2, 10 mM β-mercaptoethanol, and 200 μM vanadate] and incubated at room temperature (RT) for 30 minutes. The reaction is stopped by transferring 25 μL of reaction mixture from each well to corresponding wells of fresh Ni-chelate-coated plates and incubated overnight at 4 °C followed by 2 hours at 37 °C. To detect phosphorylation of 4E-BP1, the plates are washed once with TBST (Tris-buffered saline containing 0.1% Tween-20) containing 5% skim milk powder. To each well, 25 μL of 1:1,000 diluted phospho-4E-BP1 antibodies in TBST containing 5% skim milk are added and incubated for 1 hour at RT. The plates are washed once with TBST and then 25 μL of anti-rabbit HRP (diluted 1:10,000) in TBST containing 5% skim milk is added. The plates are incubated for 1 hour at RT and washed 5 times with TBST. For detection of phospho-4E-BP1, 25 μL of chemiluminescent reagents A+B is added and chemiluminescence is measured using an Analyst plate reader.



細胞株 U937, KG-1, KBM-3B, ML-1, HL-60, and MEG-01
濃度 0-10 μM
反応時間 72 hours

Inhibition of proliferation is measured using the Cell Titer Glo Assay , as noted in figure legends. To generate dose–response curves, cell lines are seeded at a density of 5,000 cells per well in a 96-well plate. After 24 hours of plating, cells are dosed with varying concentrations of either OSI-027 or rapamycin. The signal for Cell Titer Glo Assay is determined 72 hours after dosing and normalized to that of vehicle-treated controls. Inhibition of proliferation, relative to vehicle-treated controls, is expressed as a fraction of 1 and graphed using PRISM software.



動物モデル GEO colorectal cells are injected s.c. into the right flank of nu/nu CD-1 mice.
製剤 Dissolved in DMSO and then diluted in water.
投薬量 ≤65 mg/kg
投与方法 Administered via gavage.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download OSI-027 SDF
分子量 406.44


CAS No. 936890-98-1
保管 3年-20℃
2年-80℃in solvent
別名 ASP4786
溶解度 (25°C) * In vitro DMSO 18 mg/mL (44.28 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 (1r,4r)-4-(4-amino-5-(7-methoxy-1H-indol-2-yl)imidazo[1,5-f][1,2,4]triazin-7-yl)cyclohexanecarboxylic acid

文献中の引用 (6)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485は一種の有効的で、細胞浸透性 mTOR 活性剤で、オートファジー(autophagy)も有効に抑制します。

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021)は一種のGSK-3αとGSK-3β阻害剤で、IC50値が10 nM と6.7 nMに分かれます。

  • Dorsomorphin (Compound C, BML-275)

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183)は一種の有効的で、経口生物利用可能なAkt阻害剤で、Akt1、Akt2とAkt3に作用する時のKi値が0.08 nM、2 nMと2.6 nMそれぞれに分かれます。臨床2期。

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。

  • Everolimus (RAD001)

    Everolimus (RAD001)は一種のmTOR阻害剤で、FKBP12に作用します。無細胞試験でIC50値は1.6-2.4 nMになります。

  • AZD8055

    AZD8055は一種の新たなATP競争性mTOR阻害剤で、MDA-MB-468細胞の中でIC50値は0.8 nMです。AZD8055はmTORに作用する選択性はPI3K亜型とATM/DNA-PKに作用する選択性より約1000倍が高くなります。臨床1期。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1は一種の有効なmTORC1/2阻害剤で、無細胞試験でIC50値が2 nM/10 nMになって、mTORに作用する選択性はPI3Kに作用する選択性より1000倍が高くなります。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は一種の特定なmTOR阻害剤で、無細胞試験でIC50値は1.76 μMです。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は一種の有効的で、選択性mTOR阻害剤で、無細胞試験でこのIC50値が1 nMです。INK 128 (MLN0128)はmTORに作用する効果はI型PI3K亜型に作用する効果より200倍以上が高くなります。ラパマイシン(Rapamycin)に比べて、INK 128 (MLN0128)は優先にmTORC1/2を抑制し、促侵入遺伝子( pro-invasion genes )に敏感です。臨床1期。


Tags: OSI-027を買う | OSI-027供給者 | OSI-027を購入する | OSI-027費用 | OSI-027生産者 | オーダーOSI-027 | OSI-027代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID